background
patchouli
alcohol
pa
tricycl
sesquiterpen
extract
pogostemoni
herba
tradit
chines
medicin
use
therapi
inflammatori
diseas
recent
studi
shown
pa
variou
pharmacolog
activ
includ
antibacteri
antivir
effect
method
studi
antiinfluenza
viru
iav
activ
mechan
investig
vitro
vivo
inhibitori
effect
pa
iav
vitro
evalu
plaqu
assay
immunofluoresc
assay
neuraminidas
inhibit
assay
hemagglutin
inhibit
hi
assay
western
blot
assay
use
explor
antivir
mechan
antiiav
activ
vivo
determin
mice
pneumonia
model
stain
result
show
pa
significantli
inhibit
differ
iav
strain
multipl
vitro
may
block
iav
infect
inactiv
viru
particl
directli
interf
earli
stage
viru
adsorpt
cellular
erkmapk
signal
pathway
may
involv
antiiav
action
pa
intranas
administr
pa
markedli
improv
mice
surviv
attenu
pneumonia
symptom
iav
infect
mice
compar
effect
oseltamivir
conclus
therefor
patchouli
alcohol
potenti
develop
novel
antiiav
agent
futur
influenza
viru
iav
belong
orthomyxovirida
famili
segment
singl
strand
neg
sens
rna
virus
iav
caus
least
three
largescal
influenza
outbreak
twentieth
centuri
seriou
spanish
influenza
outbreak
caus
million
death
recent
emerg
global
spread
influenza
pandem
recent
lethal
case
influenza
demonstr
limit
current
avail
strategi
control
influenza
infect
current
three
main
type
antiiav
drug
approv
clinic
use
ion
channel
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
peramivir
polymeras
inhibitor
baloxavir
howev
emerg
drugresist
influenza
variant
amantadin
oseltamivir
resist
iav
strain
led
declin
efficaci
drug
addit
antiiav
drug
also
side
effect
nervou
system
damag
therefor
new
influenza
therapeut
novel
mechan
action
urgent
requir
combat
persist
threat
influenza
virus
patchouli
alcohol
tricycl
sesquiterpen
extract
pogostemoni
herba
long
use
treatment
inflammatori
diseas
tradit
chines
medicin
recent
studi
shown
patchouli
oil
variou
pharmacolog
activ
includ
antiemet
antiinflammatori
antibacteri
antivir
effect
li
et
al
found
oral
administr
pa
appear
abl
augment
protect
influenza
viru
infect
mice
via
enhanc
host
immun
respons
attenu
system
pulmonari
inflammatori
respons
wu
cowork
report
patchouli
alcohol
inhibit
influenza
viru
mainli
interf
function
viru
neuraminidas
therefor
pa
potenti
develop
novel
antivir
agent
futur
correl
potenti
antiiav
applic
pa
underli
molecular
mechan
antiiav
effect
mechan
pa
investig
vitro
vivo
studi
result
show
pa
may
block
iav
infect
inactiv
iav
directli
interf
earli
step
viru
adsorpt
cellular
erk
mapk
signal
pathway
may
involv
antiiav
action
pa
addit
intranas
administr
pa
markedli
improv
mice
surviv
attenu
pneumonia
symptom
iav
infect
mice
patchouli
alcohol
pa
puriti
purchas
targetmol
shanghai
china
dulbecco
modifi
eagl
medium
dmem
penicillin
streptomycin
purchas
gibco
grand
island
ny
usa
fetal
bovin
serum
fb
obtain
excel
suzhou
china
mous
antiinfluenza
viru
np
antibodi
alkalin
phosphatas
ap
label
secondari
antibodi
obtain
santa
cruz
biotechnolog
usa
dylight
conjug
secondari
antibodi
obtain
abbkin
california
usa
ribavirin
inject
mgml
purchas
lukang
cisen
jine
china
oseltamivir
carboxyl
purchas
santa
cruz
biotechnolog
santa
cruz
ca
usa
oseltamivir
phosphat
obtain
roch
shanghai
china
influenza
neuraminidas
inhibitor
detect
kit
purchas
beyotim
shanghai
china
antinp
protein
provid
abcam
antibodi
antiphosphoryl
akt
mtor
antibodi
antigapdh
antibodi
obtain
cell
signal
technolog
danver
usa
madindarbi
canin
kidney
mdck
cell
grown
dmem
medium
supplement
fb
uml
penicillin
streptomycin
cell
cultiv
medium
contain
fb
mm
lglutamin
influenza
viru
apuerto
avirginia
propag
embryon
egg
day
infect
viru
propag
solut
dilut
pb
contain
bovin
serum
albumin
bsa
ad
cell
indic
multipl
infect
moi
viru
allow
adsorb
min
remov
viru
inoculum
cell
maintain
infect
media
dmem
trypsin
co
cytotox
compound
measur
mtt
sigmaaldrich
usa
assay
confluent
mdck
cell
cultur
plate
expos
differ
concentr
pa
triplic
h
ul
pb
contain
mtt
final
concentr
mgml
ad
well
h
incub
supernat
remov
ul
dmso
ad
well
solubil
formazan
crystal
vigor
shake
absorb
valu
measur
micropl
reader
biorad
usa
nm
cc
calcul
compound
concentr
necessari
reduc
cell
viabil
differ
concentr
pa
dmem
media
mix
equal
volum
infecti
iav
pfu
well
dmem
incub
h
viruspa
mixtur
transfer
confluent
mdck
cell
monolay
plate
incub
h
gentl
shake
everi
min
inoculum
remov
well
overlaid
ml
agar
overlay
medium
agaros
deae
dextran
mm
lglutamin
mm
nonessenti
amino
acid
uml
penicillin
mgml
streptomycin
mgml
tpck
treat
trypsin
incub
day
co
cell
fix
paraformaldehyd
pfa
follow
stain
crystal
violet
plaqu
count
mdck
cell
infect
moi
four
differ
treatment
condit
pretreat
viru
iav
pretreat
pa
h
infect
ii
pretreat
cell
mdck
cell
pretreat
pa
h
infect
iii
adsorpt
mdck
cell
infect
media
contain
pa
h
adsorpt
overlaid
compoundfre
media
iv
adsorpt
h
adsorpt
inoculum
remov
infect
media
contain
pa
ad
cell
h
pi
antivir
activ
determin
plaqu
assay
mean
percentag
viru
titer
calcul
percentag
plaqu
titer
untreat
control
group
iav
viru
moi
infect
cell
treat
without
pa
adsorpt
h
post
infect
mdck
cell
fix
pfa
min
cell
permeabil
incub
sequenti
primari
antibodi
iav
np
protein
dylight
conjug
secondari
antibodi
wash
cell
nucleu
stain
dapi
min
confoc
imag
imag
record
use
nikon
confoc
microscop
analyz
imagej
nih
version
u
usa
hemagglutin
ha
assay
perform
previous
report
standard
chicken
red
blood
cell
crbc
solut
prepar
accord
manual
viru
propag
solut
serial
dilut
round
bottom
plate
crbc
ad
equal
volum
min
incub
rbc
neg
well
sediment
form
red
button
wherea
posit
well
opaqu
appear
sediment
cell
cultur
well
plate
h
transfect
plasmid
encod
viru
polymeras
subunit
pa
protein
viru
nucleoprotein
np
luciferas
rna
express
vector
cell
treat
without
pa
nucleozin
effect
vrna
transcript
evalu
measur
luciferas
activ
accord
manufactur
instruct
incub
h
influenza
neuraminidas
inhibitor
detect
kit
use
measur
inhibit
na
activ
briefli
inactiv
viru
supernat
ad
plate
mix
differ
compound
dilut
mm
me
buffer
ph
mm
cacl
min
munana
ad
substrat
incub
min
reaction
stop
addit
stop
solut
ethanol
glycin
ph
fluoresc
measur
use
spectramax
plate
reader
excit
emiss
wavelength
nm
respect
total
rna
extract
viru
moi
infect
mdck
cell
use
plu
kit
takara
japan
analys
use
one
step
sybr
primescript
rtpcr
kit
takara
japan
realtim
rtpcr
perform
use
follow
primer
viru
ha
mrna
mrna
realtim
rtpcr
perform
min
cycl
follow
melt
curv
analysi
accord
instrument
document
abi
prism
appli
biosystem
usa
rel
amount
viru
ha
mrna
molecul
determin
use
compar
method
previous
describ
drug
treatment
cell
lysat
separ
sdspage
transfer
nitrocellulos
membran
block
trisbuff
salin
tb
contain
tween
vv
bsa
wv
room
temperatur
h
membran
rins
incub
overnight
antinp
protein
santa
cruz
usa
antiphosphoryl
akt
antibodi
antigapdh
antibodi
cell
signal
technolog
danver
usa
control
membran
wash
incub
aplabel
secondari
antibodi
dilut
rt
h
protein
band
visual
incub
develop
solut
pnitro
blue
tetrazolium
chlorid
nbt
phosphat
toluidin
bcip
rt
min
rel
densiti
protein
determin
use
imagej
nih
u
usa
fourweekold
femal
kunm
mice
averag
weight
g
hous
studi
protocol
approv
anim
care
use
committe
ocean
univers
china
mice
receiv
human
care
accord
guidelin
provid
nation
institut
health
use
anim
laboratori
experi
mice
per
group
inocul
intranas
mous
dilut
ul
pb
mice
randomli
divid
experiment
group
four
hour
inocul
mice
receiv
intranas
therapi
pa
oral
therapi
oseltamivir
phosphat
mgkgday
treatment
repeat
daili
day
mice
weigh
kill
day
inocul
lung
remov
weigh
homogen
pb
determin
viral
titer
plaqu
assay
histopatholog
analysi
perform
use
h
e
stain
sampl
collect
day
post
infect
dpi
describ
previous
surviv
experi
mice
per
group
intranas
infect
viru
ld
mous
day
drug
administr
repeat
daili
experi
surviv
assess
group
day
infect
mice
monitor
daili
weight
loss
clinic
sign
mous
lost
bodi
weight
preinfect
weight
defin
dead
human
euthan
immedi
rest
mice
sacrif
end
experi
dpi
data
repres
least
three
independ
experi
data
present
mean
standard
deviat
sd
statist
signific
calcul
graphpad
prism
softwar
use
oneway
anova
turkey
test
p
valu
consid
signific
cytotox
patchouli
alcohol
pa
firstli
evalu
mtt
assay
mdck
cell
result
show
pa
exhibit
signific
cytotox
concentr
fig
cc
cytotox
concentr
valu
pa
mdck
cell
respect
result
use
determin
dose
rang
pa
subsequ
experi
pa
assay
abil
inhibit
iav
multipl
vitro
use
plaqu
assay
firstli
inhibit
pa
viru
yield
mdck
cell
infect
nw
apuerto
high
moi
pfucel
examin
plaqu
assay
shown
fig
c
pa
treatment
reduc
viru
titer
nw
dosedepend
manner
use
concentr
ml
inhibitori
concentr
ic
valu
pa
nw
respect
tabl
concentr
viru
titer
reduc
fold
untreat
control
group
fold
nw
fold
viru
fig
c
explor
whether
pa
direct
inhibit
action
viral
particl
plaqu
reduct
assay
perform
previous
describ
brief
viru
pfuwel
preincub
without
pa
min
infect
ten
viruspa
mixtur
transfer
confluent
cell
monolay
plate
incub
h
subject
plaqu
assay
shown
fig
e
preincub
pa
concentr
markedli
reduc
number
plaqu
protect
mdck
cell
suggest
pa
may
abl
inactiv
viral
particl
directli
furthermor
inhibit
effect
pa
iav
infect
also
examin
multipl
cycl
infect
use
plaqu
reduct
assay
briefli
mdck
cell
infect
pa
pretreat
viru
nw
moi
pfu
h
subject
plaqu
assay
shown
fig
pa
also
significantli
inhibit
plaqu
format
nw
moi
infect
cell
use
concentr
fig
ic
valu
pa
nw
respect
tabl
howev
ribavirin
could
significantli
inhibit
plaqu
format
ic
valu
tabl
thu
pa
possess
antiiav
effect
vitro
pandem
viru
suscept
pa
treatment
variou
timepoint
assess
determin
stage
pa
exert
inhibitori
effect
vitro
briefli
mdck
cell
infect
viru
moi
four
differ
treatment
condit
pretreat
virus
pretreat
cell
adsorpt
adsorpt
h
pi
antivir
activ
determin
plaqu
assay
shown
fig
pretreat
viru
pa
h
infect
markedli
reduc
viru
titer
suggest
pa
may
direct
interact
iav
particl
howev
either
addit
pa
adsorpt
pretreat
cell
weakli
inhibit
viru
multipl
fig
suggest
pa
may
interact
mdck
cell
directli
interestingli
treatment
pa
adsorpt
also
significantli
reduc
viru
titer
compar
nontreat
viru
control
group
fig
thu
pa
may
abl
inactiv
viru
particl
directli
block
stage
viru
adsorpt
moreov
anoth
time
cours
studi
also
perform
explor
viral
stage
adsorpt
inhibit
pa
describ
previous
briefli
fig
sinc
pa
may
abl
inactiv
viru
particl
directli
explor
whether
pa
direct
interact
viru
surfac
na
ha
protein
use
neuraminidas
inhibit
assay
hemagglutin
inhibit
hi
assay
shown
fig
pa
could
significantli
inhibit
na
activ
viru
concentr
zanamivir
possess
high
inhibit
percentag
ml
suggest
pa
may
direct
interact
viru
na
protein
moreov
result
hi
assay
show
antiha
antibodi
significantli
inhibit
virusinduc
aggreg
chicken
erythrocyt
concentr
fig
suggest
antiha
antibodi
block
viru
attach
red
blood
cell
bind
ha
howev
pa
obvious
inhibit
virusinduc
aggreg
chicken
erythrocyt
even
concentr
fig
suggest
pa
may
direct
interact
viral
ha
protein
furthermor
also
perform
minigenom
assay
evalu
influenc
pa
viral
genom
replic
occur
earli
stage
viral
life
cycl
briefli
cell
transfect
four
express
plasmid
encod
viru
pa
np
protein
luciferasecontain
plasmid
encod
virallik
genom
absenc
presenc
pa
effect
vrna
transcript
evalu
measur
luciferas
activ
h
pi
result
show
posit
drug
nucleozin
caus
notabl
reduct
luciferas
activ
compar
control
dmso
treatment
fig
contrast
treatment
pa
significantli
inhibit
luciferas
activ
suggest
np
protein
may
direct
target
pa
summari
viru
ha
na
np
protein
may
main
target
pa
vitro
sinc
pa
may
inhibit
step
viru
adsorpt
fig
b
effect
pa
viral
protein
synthesi
rna
replic
evalu
use
immunofluoresc
assay
realtim
rtpcr
assay
describ
previous
firstli
viru
moi
infect
cell
ad
pa
viru
adsorpt
incub
h
viral
np
protein
express
detect
immunofluoresc
assay
shown
fig
virusinfect
cell
without
drug
treatment
fluoresc
viral
np
protein
could
obvious
found
cell
nucleu
cytoplasm
fig
nearli
non
fluoresc
could
found
noninfect
cell
fig
howev
treatment
pa
h
number
viru
antigenexpress
cell
drastic
reduc
fluoresc
could
found
cytoplasm
fig
quantit
data
fluoresc
intens
iav
infect
cell
show
pa
treatment
significantli
reduc
fluoresc
intens
np
cell
suggest
pa
may
block
step
iav
life
cycl
adsorpt
interf
nuclear
import
express
np
protein
fig
moreov
inhibit
effect
pa
viru
mrna
express
evalu
realtim
rtpcr
assay
iav
moi
infect
cell
ad
pa
viru
adsorpt
incub
h
total
rna
extract
realtim
rtpcr
shown
fig
treatment
pa
h
iav
np
mrna
level
decreas
untreat
cell
pa
treatment
respect
consist
result
immunofluoresc
assay
furthermor
western
blot
assay
also
perform
verifi
inhibit
pa
viral
protein
product
mdck
cell
firstli
infect
iav
moi
treat
without
pa
indic
concentr
adsorpt
incub
h
viral
np
protein
product
detect
western
blot
assay
shown
fig
e
level
viral
np
protein
significantli
reduc
pa
dosedepend
manner
compar
nontreat
viru
control
group
p
treatment
pa
reduc
product
iav
np
protein
fig
therefor
pa
may
also
abl
inhibit
iav
protein
mrna
express
interf
earli
step
viru
life
cycl
sinc
pa
may
inhibit
step
viru
adsorpt
reduc
iav
mrna
protein
express
vitro
explor
pa
could
influenc
cellular
signal
pathway
requir
iav
infect
cellular
signal
pathway
report
requir
viru
endocytosi
replic
inhibitor
signal
could
inhibit
entri
replic
viru
studi
iav
infect
h
level
phosphoryl
protein
significantli
increas
fold
higher
normal
control
group
iav
infect
cell
p
fig
e
howev
treatment
pa
h
express
level
phosphoryl
significantli
decreas
normal
control
group
respect
p
fig
e
moreov
activ
induc
activ
downstream
signal
akt
level
phosphoryl
akt
truli
significantli
increas
viruscontrol
group
fold
higher
normal
control
group
h
pi
p
fig
f
treatment
pa
h
could
significantli
reduc
activ
akt
normal
control
group
respect
fig
f
thu
signal
pathway
may
involv
antiiav
mechan
pa
vitro
furthermor
mapk
signal
pathway
report
requir
effici
vrnp
export
nucleu
inhibitor
mapk
pathway
could
reduc
iav
replic
inflammatori
symptom
studi
protein
significantli
activ
viruscontrol
group
approxim
fold
higher
normal
control
group
h
pi
p
fig
g
howev
treatment
pa
h
express
level
phosphoryl
protein
significantli
decreas
normal
control
group
respect
p
fig
g
howev
treatment
pa
h
could
significantli
reduc
express
level
phosphoryl
protein
compar
viru
control
group
fig
h
thu
pa
may
inhibit
erkmapk
rather
pathway
interfer
iav
replic
moreov
pathway
report
associ
host
antivir
respons
explor
influenc
pa
immun
respons
use
western
blot
elisa
assay
first
evalu
direct
action
pa
cellular
pathway
noninfect
cell
use
western
blot
result
show
pa
treatment
could
significantli
influenc
activ
akt
protein
noninfect
cell
fig
b
suggest
inhibit
pathway
pa
may
relat
inhibit
iav
infect
treatment
pa
differ
time
interv
within
h
show
signific
cytotox
noninfect
cell
fig
addit
iav
infect
significantli
increas
product
cellular
viru
infect
cell
howev
pa
treatment
could
significantli
influenc
product
compar
viru
control
group
fig
suggest
pa
direct
action
cellular
antivir
respons
furthermor
also
evalu
influenc
pa
product
interleukin
mice
without
viru
infect
shown
fig
intranas
treatment
pa
four
day
signific
influenc
product
noninfect
mice
howev
pa
treatment
could
significantli
revers
reduct
iav
infect
mice
fig
suggest
enhanc
pa
typeii
interferon
system
may
relat
inhibit
iav
inhibit
vivo
thu
inhibit
pathway
pa
may
relat
inhibit
iav
infect
rather
direct
action
host
antivir
respons
antiiav
effect
pa
vivo
explor
use
mous
pneumonia
model
brief
iavinfect
mice
receiv
intranas
administr
pa
placebo
pb
daili
entir
experi
select
subset
treat
infect
mice
sacrif
day
tissu
sampl
remov
analysi
subsequ
pulmonari
viral
titer
determin
plaqu
assay
shown
fig
treatment
pa
day
pulmonari
viral
titer
significantli
decreas
compar
viru
control
group
p
suggest
intranas
therapi
pa
could
inhibit
iav
multipl
mice
lung
oral
therapi
oseltamivir
mgkgday
also
show
signific
reduct
viru
titer
mice
lung
p
fig
moreov
surviv
experi
also
perform
evalu
effect
pa
surviv
iavinfect
mice
shown
fig
intranas
administr
pa
significantli
increas
surviv
rate
compar
placebotr
control
group
p
day
post
infect
individu
placebo
group
surviv
wherea
anim
pa
treat
group
surviv
superior
oseltamivir
mgkgday
treat
group
pa
treatment
also
increas
surviv
rate
iav
infect
mice
without
signific
fig
evalu
effect
pa
viral
pneumonia
mice
histopatholog
analysi
also
perform
see
figur
previou
page
fig
influenc
patchouli
alcohol
viru
protein
mrna
express
immunofluoresc
assay
viru
np
protein
infect
cell
h
pi
scale
bar
repres
b
averag
fluoresc
intens
np
protein
measur
imagej
nih
version
usa
calcul
averag
intens
per
unit
area
cell
differ
imag
n
signific
p
p
vs
viru
control
group
c
moi
infect
mdck
cell
treat
differ
concentr
pa
incub
h
total
rna
extract
realtim
rtpcr
assay
iav
ha
mrna
cellular
mrna
rel
amount
viru
ha
mrna
determin
use
compar
method
rna
level
nondrug
treat
cell
viru
control
assign
valu
valu
mean
sd
n
signific
p
vs
viru
control
group
mdck
cell
firstli
infect
iav
moi
treat
without
pa
indic
concentr
adsorpt
h
pi
viru
np
protein
express
evalu
western
blot
blot
also
probe
protein
load
control
e
quantif
immunoblot
ratio
iav
np
protein
actin
ratio
nontreat
viru
control
group
assign
valu
data
present
mean
sd
n
signific
p
vs
viru
control
group
describ
previous
shown
fig
lung
tissu
viruscontrol
group
show
mark
infiltr
inflammatori
cell
alveolar
wall
presenc
massiv
serocellular
exud
lumen
howev
treatment
pa
day
lung
tissu
show
intact
columnar
epithelium
bronchiol
even
presenc
serocellular
exud
lumen
fig
mice
treat
oseltamivir
mgkgday
also
intact
columnar
epithelium
fig
thu
pa
may
abl
attenu
pneumonia
symptom
iav
infect
mice
natur
product
chines
medicin
attract
attent
pharmacist
patchouli
alcohol
pa
tricycl
sesquiterpen
extract
pogostemoni
herba
report
possess
antivir
activ
differ
virus
especi
influenza
viru
current
studi
found
pa
could
inhibit
differ
influenza
viru
replic
vitro
pandem
viru
suscept
pa
treatment
ic
intranas
administr
pa
significantli
promot
surviv
rate
mice
attenu
pneumonia
symptom
iav
infect
mice
compar
posit
control
drug
oseltamivir
thu
patchouli
alcohol
merit
investig
novel
antiiav
agent
futur
timeofaddit
assay
indic
pretreat
iav
pa
infect
addit
pa
adsorpt
markedli
reduc
viru
multipl
fig
suggest
pa
may
direct
inactiv
effect
iav
particl
pa
report
inhibit
viru
replic
mainli
inhibit
function
viru
neuraminidas
howev
contrast
previou
studi
found
pa
could
significantli
inhibit
na
activ
viru
significantli
block
ha
mediat
aggreg
chicken
red
blood
cell
thu
pa
may
abl
directli
bind
viru
surfac
protein
may
interfer
interact
iav
cell
receptor
interestingli
posttreat
cell
pa
adsorpt
also
dramat
inhibit
viru
multipl
suggest
pa
may
also
block
stage
viru
adsorpt
cellular
signal
pathway
known
abl
augment
replic
sever
virus
may
associ
lytic
infect
rna
dna
virus
includ
influenza
viru
inhibitor
downstream
signal
akt
could
significantli
block
viru
entri
replic
herein
patchouli
alcohol
found
abl
significantli
inhibit
phosphoryl
akt
protein
iavinfect
cell
fig
suggest
pa
may
inhibit
activ
signal
pathway
block
viru
infect
replic
howev
pa
could
influenc
activ
pathway
noninfect
cell
could
directli
enhanc
interferon
system
vitro
suggest
inhibit
pathway
pa
may
relat
inhibit
iav
infect
rather
direct
action
host
antivir
respons
moreov
mapk
signal
pathway
report
requir
effici
vrnp
export
nucleu
viru
rna
synthesi
inhibitor
mapk
pathway
could
reduc
iav
replic
inflammatori
symptom
studi
pa
significantli
reduc
activ
rather
iav
infect
cell
suggest
erkmapk
rather
pathway
may
involv
antiiav
action
pa
consid
pa
could
significantli
inhibit
viru
mrna
protein
express
iav
infect
cell
posit
pa
may
interfer
activ
erkmapk
signal
pathway
thu
inhibit
invas
subsequ
replic
iav
vivo
antiiav
effect
pa
also
explor
murin
pneumonia
model
influenza
intranas
treatment
mice
pa
markedli
improv
surviv
decreas
pulmonari
viru
titer
fig
moreov
histopatholog
analysi
indic
pa
treatment
also
see
figur
previou
page
fig
influenc
patchouli
alcohol
host
antivir
respons
cell
treat
without
pa
h
phosphoryl
akt
protein
evalu
via
western
blot
blot
also
probe
gapdh
protein
load
control
result
shown
repres
three
separ
experi
b
plot
quantifi
immunoblot
ratio
gapdh
pakt
protein
respect
ratio
nontreat
cell
mock
assign
valu
data
present
mean
sd
n
c
cell
treat
patchouli
alcohol
specifi
time
period
media
remov
cell
overlaid
compoundfre
media
h
pi
cell
viabil
cell
measur
mtt
assay
valu
mean
sd
n
viru
moi
infect
cell
treat
without
pa
h
content
cultur
supernat
detect
use
elisa
kit
valu
mean
sd
n
p
noninfect
group
mock
control
e
f
treatment
pa
four
day
noninfect
mice
e
viru
infect
mice
f
product
interleukin
lung
tissu
determin
use
elisa
kit
valu
mean
sd
n
signific
p
vs
noninfect
mock
control
group
p
vs
viru
control
group
attenu
pneumonia
symptom
iavinfect
lung
compar
effect
oseltamivir
howev
pa
treatment
exert
obviou
therapeut
effect
start
earlier
h
pi
restrict
clinic
applic
extent
differ
oral
administr
oseltamivir
pa
administr
intranas
low
dose
therapi
pa
compar
antiiav
effect
fig
antiiav
effect
patchouli
alcohol
vivo
viral
titer
lung
treatment
oseltamivir
mgkgday
pa
day
day
pulmonari
viral
titer
evalu
plaqu
assay
valu
mean
sd
n
signific
p
p
vs
viru
control
group
b
surviv
rate
iav
infect
mice
receiv
therapi
oseltamivir
mgkgday
pa
entir
experi
result
express
percentag
surviv
evalu
daili
day
signific
p
vs
viru
control
group
placebo
c
histopatholog
analys
lung
tissu
day
pi
stain
repres
micrograph
group
shown
n
micegroup
mock
noninfect
lung
control
iav
infect
lung
without
drug
oseltamivir
iav
infect
lung
oseltamivir
mgkgday
treatment
pa
iav
infect
lung
pa
treatment
pa
iav
infect
lung
pa
treatment
red
arrow
indic
presenc
inflammatori
cell
alveolar
wall
serocellular
exud
lumen
oseltamivir
mgkgday
suggest
pa
may
use
alon
combin
oseltamivir
treatment
influenza
differ
administr
summari
pa
possess
antiiav
activ
vitro
vivo
may
block
iav
infect
target
viru
particl
cellular
erkmapk
signal
pathway
although
studi
antivir
effect
pa
iav
strain
requir
advanc
drug
develop
pa
potenti
develop
novel
nasal
drop
influenza
therapi
prophylaxi
futur
